Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03970330|
Recruitment Status : Terminated (Original PI left institution, lack of funding to continue)
First Posted : May 31, 2019
Results First Posted : November 3, 2022
Last Update Posted : November 3, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Endometriosis||Drug: Naltrexone Drug: Norethindrone Acetate Drug: Placebo||Phase 3|
The central hypothesis of the research study is that low dose naltrexone (LDN), in combination with hormonal suppression of endometriosis (standard of care), will lead to significant improvement of endometriosis-related pain.
The proposal seeks to:
- determine if the addition of LDN to standard endometriosis treatments will improve patient- reported endometriosis associated pain using daily Visual Analogue Scale (VAS) scores and
- measure the impact of treatment on quality of life as measured by validated questionnaires including the Endometriosis Health Profile-30 (EHP30) and the Patient's Global Impression of Change (PGIC).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized, Double Blind, Placebo Controlled Trial|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized Double-Blind Placebo-Controlled Trial to Assess the Effectiveness of Low-Dose Naltrexone in Combination With Standard Treatment in Women With Chronic Pelvic Pain Secondary to Endometriosis|
|Actual Study Start Date :||January 16, 2020|
|Actual Primary Completion Date :||June 21, 2021|
|Actual Study Completion Date :||June 21, 2021|
Experimental: Low-Dose Naltrexone
12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
4.5mg daily dose, taken orally
Other Name: REVIA
Drug: Norethindrone Acetate
5 - 15mg daily dose, taken orally
Placebo Comparator: Placebo
12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
Drug: Norethindrone Acetate
5 - 15mg daily dose, taken orally
daily placebo pill, taken orally
- Pain Score Area Under the Curve (AUC) [ Time Frame: 12 weeks ]Pain is reported daily using the Visual Analog Scale, a 100mm horizontal line on which the patient's pain intensity is represented by a point between the extremities of 0 (no pain) and 100 (worst pain). The final outcome measure will be calculated as area under the curve from randomization through 12-weeks of intervention. AUC was calculated using the trapezoid rule. Calculated AUC per subject across this 12-week period can range from 0 - 8300.
- EHP-30 Score [ Time Frame: Baseline, 4, 8, 12, and 16 weeks ]Quality of life measured by the validated Endometriosis Health Profile (EHP-30) questionnaire. Scores range from 0 (best health status) to 100 (worst health status).
- PGIC Score (Painful Periods) [ Time Frame: 4, 8, 12 and 16 weeks ]Patient's Global Impression of Change (PGIC) scale will be used to rate painful periods. This is a 7 point scale ranging from 1 (much worse) to 7 (much better).
- PGIC Score (Nonmenstrual Pelvic Pain) [ Time Frame: 4, 8, 12 and 16 weeks ]Patient's Global Impression of Change (PGIC) scale will be used to rate nonmenstrual pelvic pain. This is a 7 point scale ranging from 1 (much worse) to 7 (much better).
- PGIC Score (Dyspareunia) [ Time Frame: 4, 8, 12 and 16 weeks ]Patient's Global Impression of Change (PGIC) scale will be used to rate pelvic pain during sex. This is a 7 point scale ranging from 1 (much worse) to 7 (much better).
- Ibuprofen Use [ Time Frame: 12 weeks ]Average # of ibuprofen 200 mg pills per week during the study treatment period
- Oxycodone Use [ Time Frame: 12 weeks ]Number of subjects who used oxycodone at any time during the study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 45 Years (Adult)|
|Sexes Eligible for Study:||Female|
|Gender Based Eligibility:||Yes|
|Gender Eligibility Description:||Endometriosis is specifically associated to females.|
|Accepts Healthy Volunteers:||No|
- Premenopausal female ages 18 to 45 years old on the day of signing informed consent.
- Must agree to use only study-specific analgesic medications during the study and is not known to be intolerant to them.
- Diagnosed with endometriosis and has had, within the last 10 years prior to signing the informed consent, surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis.
- Is not expected to undergo gynecological surgery or other surgical procedures for treatment of endometriosis during the study period.
- Agrees to use contraception if not surgically sterile during the entire study.
- Patients using oral contraceptives, LARCs and/or GnRH agonists/antagonists for contraception and/or management of endometriosis, with a stable regimen, will be able to continue in the study, however, women using oral contraceptives and GnRH agonist/antagonists will be switched to Norethindrone acetate during the 1-2 week run-in period as prescribed by principle investigator.
- Women that are pregnant, breastfeeding or trying to conceive.
- Patients with chronic daily narcotic use and any chronic pain or frequently reoccurring pain condition, other than endometriosis, that is treated with opioids or requires analgesics for more than 7 days per month.
- Patients with abnormal liver function tests (greater than 3x normal limit) in the past year or history of liver disease. Routine screening of liver function is not required.
- Non-English speaking or inability to read and understand English secondary, in part, to the need to read and report daily results in English.
- Undiagnosed vaginal bleeding
- Patients with history of opioid, illicit drug or alcohol abuse
- Patients currently taking thioridazine
- Patients with a history of suicidality
- Patients with current or history of unstable depression or other psychiatric disorder who, by PI judgement, are unstable or not well controlled
- Known, suspected or history of cancer of the breast
- Active deep vein thrombosis, pulmonary embolism or history of these conditions
- Active or recent arterial thromboembolic disease (e.g., stroke, myocardial infarction)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03970330
|United States, Pennsylvania|
|Penn State Hershey Medical Center|
|Hershey, Pennsylvania, United States, 17033|
|Principal Investigator:||Kristin Riley, MD||Milton S. Hershey Medical Center|
Documents provided by Kristin Riley, MD, Milton S. Hershey Medical Center:
|Responsible Party:||Kristin Riley, MD, Asst. Professor of Obstetrics and Gynecology, Milton S. Hershey Medical Center|
|Other Study ID Numbers:||
|First Posted:||May 31, 2019 Key Record Dates|
|Results First Posted:||November 3, 2022|
|Last Update Posted:||November 3, 2022|
|Last Verified:||October 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Participant data will be shared that underlie the results reported in this article, after deidentification. Documents that will be available are the study protocol, statistical analysis plan, informed consent. Analyses is to achieve the study aims in the approved proposal.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
|Time Frame:||Data will be available one year after publication according to PMCID journal guidelines.|
|Access Criteria:||Data will plan to be published in a peer-reviewed journal and /or posted at clinicaltrials.gov websites or other websites per request of the NIH. Materials will also be accessible through email contact of Primary Investigator.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Contraceptives, Oral, Hormonal
Contraceptive Agents, Female
Reproductive Control Agents
Contraceptive Agents, Hormonal
Contraceptives, Oral, Synthetic